Should you buy Moderna stock? (January 2024)

See more of my work at: https://www.3minutebreakdowns.com Moderna stock analysis. Ticker: $MRNA Moderna recently gave an update on its new cancer vaccine. When combined with the drug Keytruda, it cut the chance of late stage skin cancer from returning (after 3 years) by 49%. Since the news was announced, Moderna's stock has gained about 24%, taking the market cap to $38 billion. Despite that, shares are still down 44% over the past year. The fall in share price is hardly surprising since demand for Moderna's COVID vaccine (it's only commercial product) has collapsed. You can see that revenue grew from $60 million in 2019 to $19 billion in 2021, but it's fallen below $10 billion this year and management expects next year's revenue to be only $4 billion. On the plus side, Moderna has held on to lots of the cash it made during the pandemic. #modernastock #stockmarket #investing